Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

microRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting Rab18

Authors: Keng Zhong, Kun Chen, Lin Han, Bailing Li

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

MicroRNAs (miRNAs) are small noncoding RNAs that post-transcriptional regulate gene expression in a variety of cancers. Increasing evidences indicate that miR-30 expression is down-regulated in numerous human cancers including non-small cell lung cancer (NSCLC) which hypothesizes that miR-30 may play an important role in tumorigenesis. The aim of this study was to investigate the target gene of miR-30 and its roles in tumor growth of NSCLC.

Methods

Luciferase reporter assays were employed to validate regulation of a putative target of miR-30. The effect of miR-30 on endogenous levels of this target were subsequently confirmed via Western blot (WB). Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed to determine the expression level of miR-30 in NSCLC specimens and adjacent non-tumor tissues. MTT assays were conducted to explore the impact of miR-30 overexpression on the proliferation of human NSCLC cells.

Results

Both miR-30b and miR-30c (miR-30b/c) were found having target site in same region of Rab18 mRNA. Luciferase assays using a reporter carrying a putative miR-30b/c target site in the coding DNA sequence (CDS) region of Rab18 revealed that miR-30b/c directly targeted Rab18. Overexpression of miR-30b/c led to down-regulation of Rab18 in A549 and H23 cells at protein levels but not mRNA levels. Down-regulation of miR-30b/c and up-regulation of Rab18 protein levels were detected in NSCLC specimens compared with adjacent non-tumor tissues. Overexpression of miR-30b/c suppressed NSCLC cells growth. Knockdown of Rab18 by siRNA significantly inhibited the proliferation of NSCLC cells.

Conclusions

We demonstrated that miR-30b/c was down-regulated in NSCLC specimens compared with adjacent non-tumor tissues. miR-30b/c directly targeted and down-regulated Rab18 expression and inhibited NSCLC cells proliferation. These data indicated that miR-30b/c could serve as a tumor suppressor gene involved in NSCLC pathogenesis.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107.CrossRefPubMed
2.
Wood AJJ, Spira A, Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med. 2004, 350 (4): 379-392. 10.1056/NEJMra035536.CrossRef
3.
Yang L, Parkin DM, Ferlay J, Li L, Chen Y: Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomark Prev. 2005, 14 (1): 243-250.
4.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127 (12): 2893-2917. 10.1002/ijc.25516.CrossRefPubMed
5.
Stefani G, Slack FJ: Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol. 2008, 9 (3): 219-230. 10.1038/nrm2347.CrossRefPubMed
6.
Fabian MR, Sonenberg N, Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010, 79: 351-379. 10.1146/annurev-biochem-060308-103103.CrossRefPubMed
7.
Zhao J-J, Yang J, Lin J, Yao N, Zhu Y, Zheng J, Xu J, Cheng JQ, Lin J-Y, Ma X: Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst. 2009, 25 (1): 13-20. 10.1007/s00381-008-0701-x.CrossRefPubMed
8.
Hassan O, Ahmad A, Sethi S, Sarkar FH: Recent updates on the role of microRNAs in prostate cancer. J Hematol Oncol. 2012, 5 (9): 13-
9.
Du L, Pertsemlidis A: microRNA regulation of cell viability and drug sensitivity in lung cancer. Expert Opin Biol Ther. 2012, 12 (9): 1221-1239. 10.1517/14712598.2012.697149.CrossRefPubMed
10.
11.
Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D, Bottoni A, Garofalo M, Gasparini P, Condorelli G: miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene. 2011, 31 (5): 634-642.PubMedPubMedCentral
12.
Jeon HS, Lee SY, Lee EJ, Yun SC, Cha EJ, Choi E, Na MJ, Park JY, Kang J, Son JW: Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer. Lung Cancer. 2012, 76 (2): 171-176. 10.1016/j.lungcan.2011.10.012.CrossRefPubMed
13.
Zhang J-G, Wang J-J, Zhao F, Liu Q, Jiang K, Yang G-H: MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 2010, 411 (11): 846-852.CrossRefPubMed
14.
Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H: Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol. 2009, 27 (12): 2030-2037. 10.1200/JCO.2008.19.4134.CrossRefPubMed
15.
Liu X, Sempere LF, Guo Y, Korc M, Kauppinen S, Freemantle SJ, Dmitrovsky E: Involvement of microRNAs in lung cancer biology and therapy. Transl Res. 2011, 157 (4): 200-208. 10.1016/j.trsl.2011.01.001.CrossRefPubMedPubMedCentral
16.
Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, Shu Y: Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother. 2010, 64 (6): 399-408. 10.1016/j.biopha.2010.01.018.CrossRefPubMed
17.
Yu F, Deng H, Yao H, Liu Q, Su F, Song E: Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene. 2010, 29 (29): 4194-4204. 10.1038/onc.2010.167.CrossRefPubMed
18.
Feber A, Wilson GA, Zhang L, Presneau N, Idowu B, Down TA, Rakyan VK, Noon LA, Lloyd AC, Stupka E: Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors. Genome Res. 2011, 21 (4): 515-524. 10.1101/gr.109678.110.CrossRefPubMedPubMedCentral
19.
Quintavalle C, Donnarumma E, Iaboni M, Roscigno G, Garofalo M, Romano G, Fiore D, De Marinis P, Croce CM, Condorelli G: Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. Oncogene. 2012, 31: 4001-4008.CrossRef
20.
Guan P, Yin Z, Li X, Wu W, Zhou B: Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res. 2012, 31 (1): 54-10.1186/1756-9966-31-54.CrossRefPubMedPubMedCentral
21.
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005, 33 (20): 179-10.1093/nar/gni178.CrossRef
22.
Li J, Kong X, Zhang J, Luo Q, Li X, Fang L: MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer. Cancer Cell Int. 2013, 13 (1): 7-10.1186/1475-2867-13-7.CrossRefPubMedPubMedCentral
23.
You X, Liu F, Zhang T, Li Y, Ye L, Zhang X: Hepatitis B virus X protein upregulates oncogene Rab18 to result in the dysregulation of lipogenesis and proliferation of hepatoma cells. Carcinogenesis. 2013, 34 (7): 1644-1652. 10.1093/carcin/bgt089.CrossRefPubMed
24.
Helwak A, Kudla G, Dudnakova T, Tollervey D: Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell. 2013, 153 (3): 654-665. 10.1016/j.cell.2013.03.043.CrossRefPubMedPubMedCentral
25.
Liang Y: An expression meta-analysis of predicted microRNA targets identifies a diagnostic signature for lung cancer. BMC Med Genet. 2008, 1 (1): 61-
26.
Ouzounova M, Vuong T, Ancey P-B, Ferrand M, Durand G, Kelm FL-C, Croce C, Matar C, Herceg Z, Hernandez-Vargas H: MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells. BMC Genomics. 2013, 14 (1): 139-10.1186/1471-2164-14-139.CrossRefPubMedPubMedCentral
27.
28.
Martinez I, Cazalla D, Almstead LL, Steitz JA, DiMaio D: miR-29 and miR-30 regulate B-Myb expression during cellular senescence. Proc Natl Acad Sci. 2011, 108 (2): 522-527. 10.1073/pnas.1017346108.CrossRefPubMed
29.
Chia WJ, Tang BL: Emerging roles for Rab family GTPases in human cancer. Biochim Biophys Acta. 2009, 1795 (2): 110-116.PubMed
30.
Tang BL, Ng EL: Rabs and cancer cell motility. Cell Motil Cytoskeleton. 2009, 66 (7): 365-370. 10.1002/cm.20376.CrossRefPubMed
31.
Cheng KW, Lahad JP, Gray JW, Mills GB: Emerging role of RAB GTPases in cancer and human disease. Cancer Res. 2005, 65 (7): 2516-2519. 10.1158/0008-5472.CAN-05-0573.CrossRefPubMed
32.
Bem D, Yoshimura S-I, Nunes-Bastos R, Bond FF, Kurian MA, Rahman F, Handley MTW, Hadzhiev Y, Masood I, Straatman-Iwanowska AA: Loss-of-function mutations in RAB18 cause Warburg micro syndrome. Am J Hum Genet. 2011, 88 (4): 499-507. 10.1016/j.ajhg.2011.03.012.CrossRefPubMedPubMedCentral
33.
Behrends U, Schneider I, Rössler S, Frauenknecht H, Golbeck A, Lechner B, Eigenstetter G, Zobywalski C, Müller-Weihrich S, Graubner U: Novel tumor antigens identified by autologous antibody screening of childhood medulloblastoma cDNA libraries. Int J Cancer. 2003, 106 (2): 244-251. 10.1002/ijc.11208.CrossRefPubMed
Metadata
Title
microRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting Rab18
Authors
Keng Zhong
Kun Chen
Lin Han
Bailing Li
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-703

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma

Research article

The nucleolar size is associated to the methylation status of ribosomal DNA in breast carcinomas

Research article

Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes

Research article

Selection criteria for radiofrequency ablation for colorectal liver metastases in the era of effective systemic therapy: a clinical score based proposal

Case report

FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities

Case report

Gallbladder adenocarcinoma with sarcoid-like reaction in regional lymph nodes: report of a case
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits